CXCR4靶向PET-CT在原发性醛固酮增多症中的临床价值:系统综述与Meta分析
该系统综述与Meta分析纳入14项研究共1043例患者,评估CXCR4靶向PET-CT在原发性醛固酮增多症中的应用。其对醛固酮分泌侧化的汇总敏感度为74%、特异度为85%,鉴别醛固酮生成腺瘤与非醛固酮生成腺瘤的敏感度为91%、特异度为92%,预测术后结局的敏感度为91%、准确率为77%。作者认为其可作为原发性醛固酮增多症临床管理的辅助工具。
要点
- CXCR4靶向PET-CT侧化醛固酮分泌的汇总敏感度74%、特异度85%。
- 鉴别醛固酮生成腺瘤与非醛固酮生成腺瘤的敏感度91%、特异度92%。
- 预测术后结局的敏感度91%、准确率77%。
核心结论
- CXCR4靶向PET-CT可准确判断原发性醛固酮增多症侧化且特异度高,能可靠区分亚型并有效预测术后获益,作者认为其有潜力作为临床管理的辅助工具。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Embase、Scopus、Web of Science、万方和CNKI截至2025年1月10日的文献,纳入14项研究共1043例患者。
- 纳入提供侧化、亚型鉴别或术后结局数据的研究,采用QUADAS-2工具评估偏倚风险,采用随机效应模型计算汇总诊断指标并行总结受试者工作特征曲线分析。
主要发现
- 侧化醛固酮分泌的汇总敏感度为74%[95%CI: 69-79%],特异度为85%[95%CI: 64-95%]。
- 鉴别醛固酮生成腺瘤与非醛固酮生成腺瘤的敏感度为91%[95%CI: 82-96%],特异度为92%[95%CI: 85-96%]。
- 预测术后结局的敏感度为91%[95%CI: 84-95%],准确率为77%[95%CI: 64-90%]。
临床怎么用
- 作者认为CXCR4靶向PET-CT有潜力作为原发性醛固酮增多症临床管理的辅助工具。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Primary aldosteronism (PA), a common cause of secondary hypertension, requires precise localization and subtype differentiation for appropriate management. C-X-C chemokine receptor 4 (CXCR4) targeted PET-CT emerges as a promising non-invasive modality for evaluating PA. This study aims to assess its performance in three key areas: lateralizing aldosterone secretion, differentiating PA subtypes, and predicting surgical outcomes. METHODS: A systematic review and meta-analysis were performed, including studies that evaluated CXCR4-targeted PET-CT for PA diagnosis. Relevant literature was retrieved from PubMed, Embase, Scopus, Web of Science, WanFang, and CNKI (through January 10, 2025). Studies were included if they provided data on lateralization, subtype differentiation, or postoperative outcomes. Risk of bias was assessed using the QUADAS-2 tool. Pooled diagnostic metrics were calculated using random-effects models, with summary receiver operating characteristic curves analysis. RESULTS: Fourteen studies involving 1043 patients were included. CXCR4-targeted PET-CT demonstrated a pooled sensitivity of 74%[95%CI: 69-79%] and specificity of 85%[95%CI: 64-95%] for lateralizing aldosterone secretion. For subtype differentiation, sensitivity was 91%[95%CI: 82-96%] and specificity 92%[95%CI: 85-96%] in distinguishing aldosterone-producing adenoma from non- aldosterone-producing adenoma. In predicting postoperative outcomes, the sensitivity was 91%[95%CI: 84-95%], with accuracy of 77%[95%CI: 64-90%]. CONCLUSION: CXCR4-targeted PET-CT demonstrated clinical applications in: (1) accurately determining PA lateralization with high specificity; (2) reliably distinguishing PA subtypes; and (3) effectively predicting postoperative benefit. These findings support its potential use as an adjunctive tool in the clinical management of PA. SYSTEMATIC REVIEW REGISTRATION NO: CRD42025636887 (PROSPERO).
引用
- Tang R, Pu J, Huang Z, et al. Clinical value of CXCR4-targeted PET-CT in primary aldosteronism: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2025. PMID: 40304781. doi:10.1007/s00259-025-07312-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。